Globus Medical Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Dan Scavilla
Chief executive officer
US$4.6m
Total compensation
| CEO salary percentage | 10.2% |
| CEO tenure | 2.6yrs |
| CEO ownership | n/a |
| Management average tenure | 5.6yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Globus Medical Stock: Re-Rated After A Solid Year
Nov 18Globus Medical (NYSE:GMED) Has A Rock Solid Balance Sheet
Nov 04
Globus Medical, Inc.'s (NYSE:GMED) Shareholders Might Be Looking For Exit
Oct 14Globus Medical: A Post Acquisition Analysis
Aug 26Globus Medical, Inc.'s (NYSE:GMED) Earnings Haven't Escaped The Attention Of Investors
Jun 28An Intrinsic Calculation For Globus Medical, Inc. (NYSE:GMED) Suggests It's 42% Undervalued
Apr 08Globus Medical (NYSE:GMED) Seems To Use Debt Rather Sparingly
Mar 20Globus Medical Q4: Greater Dis-Synergies Hold Back The Stock
Feb 27Is Now An Opportune Moment To Examine Globus Medical, Inc. (NYSE:GMED)?
Feb 09Globus Medical, Inc.'s (NYSE:GMED) Price In Tune With Earnings
Jan 17Globus Medical: Merger Overhang Lingering
Nov 27Does Globus Medical (NYSE:GMED) Have A Healthy Balance Sheet?
Nov 14Should You Investigate Globus Medical, Inc. (NYSE:GMED) At US$46.27?
Oct 27Globus Medical: Almost Having My Back
Sep 13Globus Medical: Slightly Too Pricey Right Now
Aug 07Globus Medical: Robotics Demand Ratcheting Higher, Reiterate Buy
Jul 18Should You Think About Buying Globus Medical, Inc. (NYSE:GMED) Now?
Jul 11Here's Why We Think Globus Medical (NYSE:GMED) Is Well Worth Watching
Jun 18Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Apr 09What Is Globus Medical, Inc.'s (NYSE:GMED) Share Price Doing?
Mar 22Do Globus Medical's (NYSE:GMED) Earnings Warrant Your Attention?
Feb 24Globus Medical Q4 2022 Earnings Preview
Feb 20Globus Medical: An Impressive Long-Term Revenue Growth Play
Jan 08Is It Too Late To Consider Buying Globus Medical, Inc. (NYSE:GMED)?
Dec 22Globus Medical (NYSE:GMED) Will Want To Turn Around Its Return Trends
Dec 01Globus Medical Non-GAAP EPS of $0.50 misses by $0.02, revenue of $254.15M in-line
Nov 08A Look At The Fair Value Of Globus Medical, Inc. (NYSE:GMED)
Oct 15Globus Medical: Compelling Long-Term Value On Offer, Buy Thesis Intact
Sep 02Globus Medical (NYSE:GMED) Will Be Hoping To Turn Its Returns On Capital Around
Sep 02Is Globus Medical, Inc. (NYSE:GMED) Potentially Undervalued?
Aug 11Globus Medical: Low Rates Sensitivity, Seeking 26% Return Objective
Jun 05Globus Medical (NYSE:GMED) May Have Issues Allocating Its Capital
May 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$92m |
| Jun 30 2024 | n/a | n/a | US$41m |
| Mar 31 2024 | n/a | n/a | US$67m |
| Dec 31 2023 | US$5m | US$464k | US$123m |
| Sep 30 2023 | n/a | n/a | US$158m |
| Jun 30 2023 | n/a | n/a | US$204m |
| Mar 31 2023 | n/a | n/a | US$201m |
| Dec 31 2022 | US$4m | US$437k | US$190m |
| Sep 30 2022 | n/a | n/a | US$155m |
| Jun 30 2022 | n/a | n/a | US$155m |
| Mar 31 2022 | n/a | n/a | US$142m |
| Dec 31 2021 | US$2m | US$396k | US$149m |
| Sep 30 2021 | n/a | n/a | US$187m |
| Jun 30 2021 | n/a | n/a | US$184m |
| Mar 31 2021 | n/a | n/a | US$122m |
| Dec 31 2020 | US$2m | US$384k | US$102m |
| Sep 30 2020 | n/a | n/a | US$95m |
| Jun 30 2020 | n/a | n/a | US$89m |
| Mar 31 2020 | n/a | n/a | US$148m |
| Dec 31 2019 | US$2m | US$366k | US$155m |
| Sep 30 2019 | n/a | n/a | US$146m |
| Jun 30 2019 | n/a | n/a | US$143m |
| Mar 31 2019 | n/a | n/a | US$150m |
| Dec 31 2018 | US$2m | US$355k | US$156m |
| Sep 30 2018 | n/a | n/a | US$144m |
| Jun 30 2018 | n/a | n/a | US$134m |
| Mar 31 2018 | n/a | n/a | US$118m |
| Dec 31 2017 | US$1m | US$345k | US$107m |
Compensation vs Market: Dan's total compensation ($USD4.56M) is below average for companies of similar size in the US market ($USD12.74M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
CEO
Dan Scavilla (59 yo)
2.6yrs
Tenure
US$4,564,374
Compensation
Mr. Daniel T. Scavilla, also known as Dan, serves as President and Chief Executive Officer at Globus Medical, Inc. since April 21, 2022 and serves as its Director since April 2022. He had been Executive Vi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 21.8yrs | US$3.22m | 16.35% $ 1.9b | |
| President | 2.6yrs | US$4.56m | no data | |
| CFO & COO | 5.3yrs | US$2.06m | 0% $ 0 | |
| Senior VP | 5.9yrs | US$1.64m | 0% $ 0 | |
| Senior Vice President of Business Development & Investor Relations | no data | no data | no data |
5.6yrs
Average Tenure
57yo
Average Age
Experienced Management: GMED's management team is seasoned and experienced (5.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 21.8yrs | US$3.22m | 16.35% $ 1.9b | |
| President | 2.6yrs | US$4.56m | no data | |
| Independent Director | 13.3yrs | US$490.69k | 0.031% $ 3.6m | |
| Independent Director | 1.2yrs | US$276.27k | 0.011% $ 1.3m | |
| Independent Director | 5.5yrs | US$470.69k | 0% $ 0 | |
| Independent Director | 9.3yrs | US$478.19k | 0% $ 0 | |
| Independent Director | 1.2yrs | US$278.15k | 0.018% $ 2.0m | |
| Independent Director | 4.9yrs | US$470.69k | 0.0015% $ 166.8k | |
| Independent Director | 21.7yrs | US$468.19k | 0.53% $ 60.2m | |
| Independent Director | 1.2yrs | US$278.77k | 0.012% $ 1.4m | |
| Independent Director | 13.6yrs | US$478.19k | no data |
5.5yrs
Average Tenure
62yo
Average Age
Experienced Board: GMED's board of directors are considered experienced (5.5 years average tenure).